No Data
Shuoshi Biology: Jiangsu Shuoshi Biotechnology Co., Ltd. 2024 Annual Performance Report Announcement
Jiangsu Shuoshi Biotechnology Co., Ltd. 2024 Annual Results Express Announcement
Jiangsu Shuoshi Biotechnology Co., Ltd. 2024 Annual Results Forecast
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH): Expected loss of 1.8 million to 2.7 million yuan in 2024.
Gelonghui, on January 24, announced that Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) has released its performance forecast for the year 2024. According to preliminary calculations by the financial department, it is expected that the net income attributable to the parent company's owners for the year 2024 will be between -2.7 million yuan and -1.8 million yuan. Compared to the same period last year (statutory disclosure data), this represents a reduction in losses of 371.1114 million yuan to 372.0114 million yuan, a year-on-year reduction in losses of 99.28% to 99.52%. It is also expected that the net income attributable to the parent company's owners after deducting non-recurring gains and losses for 2024 will be between -75 million yuan and -68 million yuan, compared to the same year last.
Orient: DNA methylation assists in the diagnosis and treatment of endometrial cancer. Pay attention to companies related to the Industry Chain.
DNA methylation has been confirmed to have auxiliary diagnostic value for early endometrial cancer. With its advantages of being earlier and less invasive, it has become one of the methods for early auxiliary diagnosis of various cancers.
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH): The actual controller has renewed the concerted action agreement.
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH) announced that it has received a notice from the actual controlling shareholders Mr. Fang Yongsheng, Mr. Liang Xilin, and Mr. Wang Guoqiang regarding the renewal of the "Joint Action Agreement". As the renewal of the "Joint Action Agreement" signed by all parties on December 5, 2023 had expired, in order to improve corporate governance, ensure the continuity and stability of the company's operation, and achieve effective and substantial control of the company, all parties renewed the "Joint Action Agreement".